JUPITER kan ge paradigmskifte i prevention av hjärt-kärlsjukdom. Fokus på inflammation som riskfaktor
Engelsk titel: JUPITER can yield paradigmatic shift in the prevention of cardiovascular disease. Focus on inflammation as a risk factor
Läs online
Författare:
Olsson AG
Email: andol@imv.liu.se
Språk: Swe
Antal referenser: 13
Dokumenttyp:
Översikt
UI-nummer: 09061759
Sammanfattning
In the JUPITER study the clinical effect of a daily dose of 20 mg rosuvastatin was tested in 17 032 non-diseased individuals with LDL cholesterol below 3.36 mmol/L and C-reactive protein (CRP) of 2.0 mg/L or more on cardiovascular events. Rosuvaststin lowered LDL cholesterol and CRP by 50 and 37 %, respectively. The primary endpoint was 0.77 and 1.36 per 100 person years in rosuvastatin and placebo treated groups, respectively, hazard ratio 0.56, p<0.00001. The JUPITER study demonstrates the role of inflammation in the atherogenic process and the need to consider this in the clinical risk evaluation for cardiovascular disease in asymptomatic individuals. Greater attention should be paid to primary prevention of cardiovascular disease in which drug treatment should be a clear option in subjects with signs of inflammation.